We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Repros (RPRX) Q4 Earnings: What's in Store for the Stock?
Read MoreHide Full Article
Repros Therapeutics Inc. (RPRX - Free Report) is expected to report fourth-quarter 2016 results this month. Let’s see how things are shaping up for this quarter.
Repros Therapeutics’ share price decreased 8.3% year to date, while the Zacks classified Medical-Biomed/Genetics industry gained 10.4%.
Repros is a development-stage biotech company focused on the development of treatments for hormonal and reproductive system disorders. With no approved products in its portfolio yet, investors are expected to remain focused on pipeline-related updates by the company. Repros’ pipeline presently comprises enclomiphene and Proellex.
The most advanced candidate in Repros’ pipeline is enclomiphene, which is currently under review in the EU. The company intends to get the candidate approved for the treatment of secondary hypogonadism. A decision on the approval status of the candidate should be out in 2017.
Moreover, Repros is conducting a placebo-controlled, double-blind, proof-of-concept phase II study (ZA-205) on enclomiphene in obese secondary hypogonadal men to assess its impact on metabolic parameters and quality of life with routine diet and exercise. Six-month interim data from the study were reported in Aug 2016.
Proellex is also being evaluated in phase II trials for the treatment of endometriosis. In Sep 2016, the company reported positive data from the first course of treatment from the ongoing phase II study on Proellex (oral administration) for the treatment of premenopausal women with confirmed symptomatic endometriosis. Repros plans to have a discussion with the FDA for phase III studies on Proellex for the treatment of women struggling with painful menstruation.
In Nov 2016, the company reported top-line results from two phase II studies evaluating both oral and vaginal administration of Proellex for the treatment of uterine fibroids. On Jan 2017 FDA has granted an “end of phase II” meeting to discuss the phase III requirements to demonstrate both efficacy and safety for the development of Proellex for uterine fibroids is scheduled to occur before the end of April this year.
We wait to see the impact of these studies on the upcoming earnings.
Stocks that Warrant a Look
Here are some health care stocks that you may want to consider, as our model shows that they have the right combination of elements – a positive Zacks Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) – to post an earnings beat this quarter.
You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Bristol-Myers Squibb Company (BMY - Free Report) has an Earnings ESP of +5.41% and a Zacks Rank #3.
Biogen Inc. (BIIB - Free Report) has an Earnings ESP of +0.60% and a Zacks Rank #3.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Repros (RPRX) Q4 Earnings: What's in Store for the Stock?
Repros Therapeutics Inc. (RPRX - Free Report) is expected to report fourth-quarter 2016 results this month. Let’s see how things are shaping up for this quarter.
Repros Therapeutics’ share price decreased 8.3% year to date, while the Zacks classified Medical-Biomed/Genetics industry gained 10.4%.
Repros is a development-stage biotech company focused on the development of treatments for hormonal and reproductive system disorders. With no approved products in its portfolio yet, investors are expected to remain focused on pipeline-related updates by the company. Repros’ pipeline presently comprises enclomiphene and Proellex.
The most advanced candidate in Repros’ pipeline is enclomiphene, which is currently under review in the EU. The company intends to get the candidate approved for the treatment of secondary hypogonadism. A decision on the approval status of the candidate should be out in 2017.
Moreover, Repros is conducting a placebo-controlled, double-blind, proof-of-concept phase II study (ZA-205) on enclomiphene in obese secondary hypogonadal men to assess its impact on metabolic parameters and quality of life with routine diet and exercise. Six-month interim data from the study were reported in Aug 2016.
Proellex is also being evaluated in phase II trials for the treatment of endometriosis. In Sep 2016, the company reported positive data from the first course of treatment from the ongoing phase II study on Proellex (oral administration) for the treatment of premenopausal women with confirmed symptomatic endometriosis. Repros plans to have a discussion with the FDA for phase III studies on Proellex for the treatment of women struggling with painful menstruation.
In Nov 2016, the company reported top-line results from two phase II studies evaluating both oral and vaginal administration of Proellex for the treatment of uterine fibroids. On Jan 2017 FDA has granted an “end of phase II” meeting to discuss the phase III requirements to demonstrate both efficacy and safety for the development of Proellex for uterine fibroids is scheduled to occur before the end of April this year.
We wait to see the impact of these studies on the upcoming earnings.
Stocks that Warrant a Look
Here are some health care stocks that you may want to consider, as our model shows that they have the right combination of elements – a positive Zacks Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) – to post an earnings beat this quarter.
You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
BioMarin Pharmaceutical Inc. (BMRN - Free Report) has an Earnings ESP of +3.13% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Bristol-Myers Squibb Company (BMY - Free Report) has an Earnings ESP of +5.41% and a Zacks Rank #3.
Biogen Inc. (BIIB - Free Report) has an Earnings ESP of +0.60% and a Zacks Rank #3.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>